Rapid advances in our understanding of the biology and pathology of ly
mphoproliferative disorders, permitted mainly by new diagnostic tools,
constantly change our approach to this heterogenous group of disorder
s. In this review of the more indolent subgroup of lymphoproliferative
disorders, some of the recent advances are highlighted, and treatment
options discussed.